Profile

Business Description

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

Company Info

Address:
500 River Ridge Drive
Norwood, MA 02062 US

Telephone:
617.963.0100

Fax:
617.663.6085

Email:
info@corbuspharma.com

Industry Classifications

Sector:
Biopharmaceutical

Industry:
Biotechnology

NAICS:
325412 – Pharmaceutical Preparation Manufacturing

SIC:
2834 – Pharmaceutical Preparations

Third-party websites are provided for convenience only. Corbus Pharmaceuticals Holdings, Inc. does not approve of, or endorse any of the content. Corbus Pharmaceuticals Holdings, Inc. does not maintain, control or monitor the content of third-party websites in any way.